A D2 partial agonist can occupy receptors that dopamine might otherwise activate. When it replaces a stronger agonist, the resulting signalling can be lower. This helps explain how a drug that activates dopamine receptors can nevertheless have antipsychotic effects. The net outcome depends on local dopamine availability and receptor biology.
A partial agonist activates a receptor less strongly than a full agonist under comparable conditions. Several antipsychotics use partial agonism at dopamine D2 receptors alongside other actions. This distinguishes them from conventional D2 antagonists, but does not make them free of adverse effects or automatically preferable for every person with psychosis.
The process is more complicated than adding dopamine where it is low and removing it where it is high. Current medicines do not independently detect an ideal setting in each circuit. Other targets and long-lasting metabolites also influence the experience. Understanding competition is useful, but it cannot predict which person will feel calmer, more activated or more restless. Clinical review should assess both psychotic symptoms and possible adverse effects rather than infer that partial agonism must always improve motivation or protect against every movement-related problem.
Competition also depends on binding affinity and concentration. A strongly binding partial agonist may occupy a large share of receptors, but the resulting signalling differs from complete blockade. This helps explain why occupancy alone can mislead when comparing drug classes. Clinical interpretation must include the type of action and the effects observed, rather than treating all occupied D2 receptors as functionally identical.
Further reading: DailyMed prescribing information (1); Cariprazine prescribing information; DailyMed prescribing information (3).
Comments are closed, but trackbacks and pingbacks are open.